Truist initiated coverage on Dexcom with a new price target
$DXCM
Medical/Dental Instruments
Health Care
Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2026 | $86.00 | Buy | Deutsche Bank |
| 5/12/2026 | $77.00 | Buy | The Benchmark Company |
| 3/24/2026 | $90.00 | In-line → Outperform | Evercore ISI |
| 1/12/2026 | $71.00 | Equal Weight → Underweight | Barclays |
| 12/2/2025 | $75.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/25/2025 | $68.00 | In-line | Evercore ISI |
| 10/21/2025 | $85.00 | Buy | Stifel |
| 9/8/2025 | Outperform → Perform | Oppenheimer |
8-K - DEXCOM INC (0001093557) (Filer)
SD - DEXCOM INC (0001093557) (Filer)
144 - DEXCOM INC (0001093557) (Subject)
Deutsche Bank initiated coverage of Dexcom with a rating of Buy and set a new price target of $86.00
The Benchmark Company initiated coverage of Dexcom with a rating of Buy and set a new price target of $77.00
Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5. Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility. D
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star
At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.The company also announced details regarding the rollout of its fully reimagined Stelo app experience launching in July in the US, helping make glucose insights more approachable and actionable for people seeking better health.Expanded international availability of Stelo is also planned for the United Kingdom, Australia, New Zealand and South Korea starting later this year and will continue into 2027.DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of mil
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025. F
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s
Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)